Evidence map›Paper›PMID 40416605›Full record

ArticlePeerJ2025

Bulk and single-cell RNA sequencing identify prognostic signatures related to FGFBP2

Yinbing Wu, Huanjun Peng, Guangkang Chen, Yinuo Tu, Xinpei Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yinbing Wu *Department of Hepatobiliary Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Huanjun Peng *Department of Hepatobiliary Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Guangkang ChenDepartment of Hepatobiliary Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Yinuo TuDepartment of Hepatobiliary Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Xinpei YuDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is a highly aggressive malignancy. As a specific immune cell subpopulation, FGFBP2 Methods: Bulk and scRNA-seq data were derived from the public databases. The single cell atlas of HCC and heterogeneity of natural killer (NK) cells were delineated by "Seurat" package. Pseudo-time trajectory of FGFBP2 Results: The proportion of NK cell in HCC samples was markedly decreased than that in healthy samples. NK cell was further divided into three cell subpopulations, and FGFBP2 Conclusion: This study identified eight prognostic gene signatures related to FGFBP2

Indexed as

Carcinoma, HepatocellularKiller Cells, NaturalLiver NeoplasmsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisSequence Analysis, RNASingle-Cell AnalysisBulk RNA sequencingFGFBP2+ NK cellHepatocellular carcinomaImmunotherapyPrognostic signatureSingle-cell RNA sequencingTumor microenvironment

Identifiers

PMID40416605
PMCPMC12101446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.